BARDA awarded Scynexis a $214 million contract to develop a treatment for invasive fungal infections. The award supports continued development in a segment where resistant and hard-to-treat pathogens drive high unmet need and long timelines. The funding underscores the U.S. government’s continued reliance on advanced development partners to translate antimicrobial candidates into clinical-stage programs. Scynexis will now prioritize clinical progress and regulatory readiness as the contract defines milestone-linked expectations.